Eculizumab treatment in patients with COVID-19
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience F. Diurno, F.G. Numis, G. Porta, F. Cirillo, S. Maddaluno, A. Ragozzino, P. De Negri, C. Di Gennaro, A. Pagano, E. Allegorico, L. Bressy, G. Bosso, A. Ferrara, C. Serra, A. Montisci, M. D’Amico, S. Schiano Lo Morello, G. Di Costanzo, A.G. Tucci, P. Marchetti, U. Di Vincenzo, I. Sorrentino, A. Casciotta, M. Fusco, C. Buonerba, M. Berretta, M....
Read More
COVID-19 (Novel Coronavirus 2019) – recent trends
Kannan, P. Shaik Syed Ali, A. Sheeza, K. Hemalatha School of Medicine, The Maldives National University, Male’, Maldives. Kannan.subbaram@mnu.edu.mv INFECTIOUS DISEASES The World Health Organization (WHO) has issued a warning that, although the 2019 novel coronavirus (COVID-19) from Wuhan City (China), is not pandemic, it should be contained to prevent the global spread. The COVID-19 virus was known earlier as 2019-nCoV. As of 12 February 2020, WHO reported 45,171 cases and 1115 deaths related...
Read More
Novel coronavirus 2019-nCoV
Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV S.A. Meo, A.M. Alhowikan, T. Al-khlaiwi, I.M. Meo, D.M. Halepoto, M. Iqbal, A.M. Usmani, W. Hajjar, N. Ahmed Department of Physiology, Strategic Centre for Diabetes Research, Thoracic Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia. sultanmeo@hotmail.com INFECTIOUS DISEASES OBJECTIVE: Human infections with zoonotic coronavirus contain emerging and reemerging pathogenic characteristics which have raised great public health concern. This study aimed at investigating...
Read More
Novel Coronavirus 2019 (Sars-CoV2)
A global emergency that needs new approaches? Perrella, N. Carannante, M. Berretta, M. Rinaldi, N. Maturo, L. Rinaldi VII Division of Infectious Diseases and Immunology, P.O. “D. Cotugno”, AORN Ospedali dei Colli, Naples, Italy. lucarinaldi@hotmail.it SCOPRI DI PIÚ
Read More